RICHMOND, Va., July 02, 2019 (GLOBE NEWSWIRE) — via NetworkWire – AVAIL Vapor, LLC, the nation’s

RICHMOND, Va., July 02, 2019 (GLOBE NEWSWIRE) — via NetworkWire – AVAIL Vapor, LLC, the nation’s leading premium e-liquid manufacturing, scientific services and retail business, today announced the company will launch Leafana Wellness with the introduction of the Leafana Wellness CBD line. The company has carried third-party CBD products since February of this year and will now sell its own Leafana Wellness CBD product line at its 99 retail stores in 12 states and offer the complete product line to U.S. distributors.   “We are excited to launch Leafana Wellness with our CBD product line,” said James Xu, Chief Executive Officer of AVAIL. “The products have been developed in direct response to needs our customers have shared with us. Leafana Wellness products provide the highest-quality natural self-care options for both our vaping and non-vaping customers.” Leafana Wellness CBD products are designed using the finest U.S. ingredients and flavorings to deliver a product that rivals the highest-quality products on the market and are available in two product lines: a liquid isolate vaping series and broad spectrum tinctures. Leafana Wellness CBD vape liquids include the flavor...

Products containing phytocannabinoids have been flooding the market since the passage of the 2018 United States

Products containing phytocannabinoids have been flooding the market since the passage of the 2018 United States Farm Bill, which lifted the prohibition under the Federal Controlled Substances Act on possessing, using, buying, selling, or cultivating cannabis. This bill gave states the liberty to legalize cannabis species containing less than 0.3% of the psychoactive phytocannabinoid, tetrahydrocannabinol (THC), which previously drove all phytocannabinoids under the cloak of Schedule 1 drugs. Aside from THC, cannabidiol (CBD) from hemp (Cannabis sativa) is the most abundant and well-researched cannabinoid and does not possess psychoactive properties.1 Clinical studies show that CBD imparts multiple health advantages, with hemp falling within the legal limits of possessing no more than 0.3% THC.1 Therefore, the legalization of certain species of cannabis raised the curtain upon CBD and phytocannabinoids more broadly. The wide range of therapeutic potential associated with phytocannabinoids has piqued interest among both health care practitioners and consumers. Research to date has supported its potential as a beneficial therapy for chronic pain, anxiety, depression, psychosis, sch...